MedTrace Logo

Eisenmenger Quality Enhancement Research Initiative

NCT01623492 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 193

Last updated 2025-02-03

No results posted yet for this study

Summary

Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment. Patient data will be collected prospectively for three years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process.

Conditions

Interventions

OTHER

Subjects with diagnosis of Eisenmenger Syndrome

1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine 2. Contraception counseling, and recommendations regarding avoidance of pregnancy 3. Documentation and prescription of the specific medications: 1. Oxygen 2. Diuretic 3. ASA, Anticoagulant 4. CCB, BB, ACEI, ARB 5. Iron Supplementation 6. Allopurinol 7. PAH specific therapy

Sponsors & Collaborators

  • Canadian Heart Research Centre

    collaborator OTHER

  • Actelion

    lead INDUSTRY

Principal Investigators

  • Michael Landzberg, MD · Harvard Medical School / Boston Adult Congenital Heart

  • Gary Palmer, MD, MBA · Actelion Pharmaceuticals U.S., Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-01
Primary Completion
2018-04-17
Completion
2018-04-17

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01623492 on ClinicalTrials.gov